Technology News and Research

RSS

Capsule expands marketing program

After extensive planning, strategizing, and consulting, Capsule, the leading provider of medical device connectivity, has announced that they are expanding their marketing program to include social media. From Twitter, to Capsule's very own Facebook fan page, Capsule is ready to engage and gain new insights in order to better serve the clinical and HIT community.

8 Sep 2009

3Dicon presents its business strategy and developments

3DIcon Corporation, the developer of groundbreaking three-dimension projection and display technologies, today provided a status report and announced several significant steps it is pursuing as a part of its business plan.

8 Sep 2009

Consumer Health Advisers raises $1.15M to expand its sales and marketing initiatives

Consumer Health Advisers, Inc. (CHA), a pioneering provider of a personal 'electronic medical home' for employees and dependents of large companies, is pleased to announce it has completed a Series A venture capital round of $1.15 million and opened a new office in Chicago, Illinois.

8 Sep 2009

New technology developed to detect counterfeit drugs

University of Leicester researchers have combined crime research and space-age technology in ways that could lead to the quick detection of counterfeit pharmaceuticals in a black market currently worth an estimated $40billion per year.

8 Sep 2009

National Health IT Week to focus on ARRA and healthcare reform

This September, Unitiv, as a partner in the advancement of health information technology, will join approximately 75 public and private sector organizations in Washington, D.C., to participate in the Fourth Annual National Health IT Week (September 21-25, 2009).

8 Sep 2009

Axel Ullrich receives the 2009 Dr. Paul Janssen Award for Biomedical Research

Johnson & Johnson today honored the career achievements of Axel Ullrich, Ph.D., with the 2009 Dr. Paul Janssen Award for Biomedical Research. Dr. Ullrich received this award for his scientific discoveries that led to innovative new drugs including Herceptin((R)) (trastuzumab)*, a personalized medicine therapy, which was the first to target a specific type of breast cancer.

8 Sep 2009

New probiotic provides protection against the fatal E. coli disease

Researchers in Australia are developing diversionary tactics to fool disease-causing bacteria in the gut. Many bacteria, including those responsible for major gut infections, such as cholera, produce toxins that damage human tissues when they bind to complex sugar receptors displayed on the surface of cells in the host's intestine.

8 Sep 2009

Oxidative DNA damage: Primary cause of mutation

A study that tracked genetic mutations through the human equivalent of about 5,000 years has demonstrated for the first time that oxidative DNA damage is a primary cause of the process of mutation - the fuel for evolution but also a leading cause of aging, cancer and other diseases.

8 Sep 2009

Renewal of CytoCare and i.v.STATION distribution agreements

Health Robotics today announced that after a successful first year of cooperation in Japan with Tosho Inc., the companies signed this week a contract renewal of the CytoCare and i.v.STATION exclusive distribution agreements, and an expansion of their strategic relationship to include future joint-development projects in their respective areas of Pharmacy Automation expertise.

7 Sep 2009

Early schizophrenia symptoms include unusually high CA1 subfield activity

In the first functional magnetic resonance imaging (fMRI) study of its kind, neurologists and psychiatrists at Columbia University have identified an area of the brain involved in the earliest stages of schizophrenia and related psychotic disorders.

7 Sep 2009

Iterative in situ click chemistry creates antibody-like protein-capture agents

Chemists at the California Institute of Technology (Caltech) and The Scripps Research Institute (SRI) have developed an innovative technique to create cheap but highly stable chemicals that have the potential to take the place of the antibodies used in many standard medical diagnostic tests. James R. Heath, Ph.D., principal investigator of the Nanosystems Biology Cancer Center at Caltech, one of eight Centers of Cancer Nanotechnology Excellence, and K. Barry Sharpless, Ph.D., SRI, and their colleagues describe the new technique in the journal Angewandte Chemie International Edition.

7 Sep 2009

Nanoparticle-delivered suicide gene therapy effectively reduces ovarian tumor burden in mice

Nanoparticle delivery of diphtheria toxin-encoding DNA that expresses selectively in ovarian cancer cells reduced the burden of ovarian tumors in mice, and researchers expect that this therapy could be tested in humans with advanced ovarian cancer within 18 to 24 months, according to a report in Cancer Research. If additional tests are successful, these finding could lead to a new treatment for ovarian cancer, which now causes more than 15,000 deaths each year in the United States. Because it is usually diagnosed at a relatively late stage, ovarian cancer is one of the most deadly forms of the disease.

7 Sep 2009

Tool to aid health organizations tackle spread of pandemic diseases

OAG, the leading provider of global airline data and intelligence, has developed a prototype to assist health organizations and government agencies in preparing their strategies to combat the spread of pandemic diseases, including the H1N1 virus and other flu strains.

7 Sep 2009

Biotechnological approach to fight H1N1 influenza

ETBOND TECHNOLOGY defines Biotechnology approach to fight H1N1 Influenza A (Swine Flu)

7 Sep 2009

3Sbio announces date for shareholders' annual general meeting

3SBio Inc.("3SBio" or "Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that the annual general meeting of shareholders of 3SBio Inc. will be held on October 12, 2009 at 10:00 a.m., Shenyang time, at No.3 A1, Road 10, Shenyang Economy & Technology Development Zone, Shenyang 110027, People's Republic of China. The shareholder record date is September 12, 2009.

7 Sep 2009

The Jordanian Stem Cell Company signs purchase agreement with Stemedica International

Stemedica Cell Technologies, Inc., ("Stemedica"), a world leader in stem cell research and manufacturing, announced the signing of an agreement today for its breakthrough stem cell and related technology. The Jordanian Stem Cell Company has signed a five year multi-million dollar agreement to purchase the technology from Stemedica's wholly-owned subsidiary, Stemedica International, S.A.

7 Sep 2009

Bacterium's S-layer secretes many therapeutic proteins

By adapting a single protein on the surface of the bacterium Caulobacter crescentus, researchers at the University of British Columbia have turned it into a protein production factory, making useful proteins that can act as vaccines and drugs. Dr. John Smit presented the findings at the Society for General Microbiology's meeting at Heriot-Watt University, Edinburgh, today (7 September).

7 Sep 2009

ASNM inaugral conference to discuss the latest in nanomedicine

Nanomedicine - the science and technology of diagnosing, treating and preventing disease to improve human health using nanotechnology - has the potential to revolutionize healthcare. Current and future products range from miniaturized "smart pills" that precision-target certain cancers to nanosensors that are capable of navigating through the body for early detection of disorders.

5 Sep 2009

Impact of the patient centered medical home model on the health care reform

Health2 Resources announced today free access to its Web portal, H2RMinutes, a one-stop source for news about the patient centered medical home (PCMH). H2RMinutes (http://www.h2rminutes.com) is designed specifically to keep health care policymakers, providers, employers and suppliers informed about the impact that the PCMH model is having on the national health care reform debate.

5 Sep 2009

Sponsor-A-Scientist program launched

The Sbarro Health Research Organization, a nonprofit center for cancer, cardiovascular and diabetes research located at Temple University in Philadelphia and the University of Siena, Italy, has launched Sponsor-A-Scientist program.

5 Sep 2009